We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment

By LabMedica International staff writers
Posted on 05 Oct 2026

CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation, clinical trial execution, regulatory readiness, and deployment. More...

The companies are currently working together on programs with two leading global pharmaceutical companies. These include an AI-powered immunohistochemistry companion diagnostic development program and a separate program applying Imagene AI’s Lung Prediction Panel in non-small cell lung cancer.

Imagene AI’s OI CDx capabilities apply quantitative AI pathology to assess biomarker and target expression. The approach includes cell and subcellular analysis, continuous and spatial scoring, and patient stratification. The collaboration also includes Imagene AI’s Multi-gene Lung Prediction Panel, which predicts key non-small cell lung cancer biomarkers directly from routine hematoxylin and eosin whole-slide images within minutes.

CellCarta supports these AI-powered approaches through analytical validation, global clinical trial deployment infrastructure, companion diagnostic development capabilities, and regulatory expertise. The Lung Prediction Panel is for Research Use Only and is not for use in diagnostic procedures. The expanded collaboration builds on Imagene AI’s participation in CellCarta’s Digital Pathology and AI Consortium, announced in July 2026, and extends the relationship into active biopharma development programs.

“Pharma companies need a practical path for translating AI-powered biomarker and image-analysis capabilities into assays that can support clinical development and companion diagnostic programs. We are pleased to join forces with CellCarta, a leader in clinical biomarker and companion diagnostic development, to support programs from assay development through commercialization. We are already applying this model across active pharma programs in both AI-powered IHC and H&E-based biomarker prediction,” said Michael Hreczuck, SVP of Business Development at Imagene AI.

Related Links
CellCarta
Imagene AI


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.